ProHealth health Vitamin and Natural Supplement Store and Health
Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|

Trending News

CDC Whistleblower Reveals Widespread Manipulation of Scientific Data and Top-Down Pressure on CDC Sc...

How Glutathione Can Save Your Life

Reversing Neurodegeneration with a New Magnesium Compound

Coenzyme Q10 Benefits Symptoms in Gulf War Veterans: Results of a Randomized Double-Blind Study

Gut Bacteria, Artificial Sweeteners and Glucose Intolerance

Brain inflammation dramatically disrupts memory retrieval networks, UCI study finds

Scientists discover how to 'switch off' autoimmune diseases

Clinical trial demonstrates safety, effectiveness of immunotherapy for AdV, BKV, and herpesviruses i...

Surprising discovery: HIV hides in gut, evading eradication

New estrogen-based compound suppresses binge-like eating behavior in female mice

 
Print Page
Email Article

Hemispherx Biopharma Releases Preliminary Findings on Ampligen For Treatment of Chronic Fatigue Syndrome at International Conference

  [ 8 votes ]   [ Discuss This Article ]
www.ProHealth.com • February 9, 2001


Hemispherx Biopharma, Inc this week released preliminary findings for the treatment of Chronic Fatigue Syndrome (CFS) with their flagship investigational drug, Ampligen®, under an expanded access program. These findings were first presented at the American Association for Chronic Fatigue Syndrome conference in Seattle, Washington in a peer-reviewed session.
The objective of this study was to review clinical endpoints including Karnofsky Performance Scores (KPS) and Cognitive Function data derived from an expanded access treatment protocol (trial AMP 511) using Ampligen® for the treatment of CFS.

Chronic Fatigue Syndrome is a symptom complex characterized by both cognitive as well as physical impairments. Although the cause of CFS remains under investigation, the presenting symptoms have been codified by the Centers for Disease Control (CDC) and prevention to assist in making a CFS diagnosis. The primary and most salient feature of CFS is persistent and pervasive fatigue and a decrease in physical performance.

Accordingly, the investigators utilized several Quality of Life (QOL) instruments, including the Karnofsky Performance Score (KPS), as well as a self-reported and physician completed instrument evaluating functionality, as endpoints assessing the clinical benefit of Ampligen®. Clinical endpoints included changes in KPS, cognitive deficit (SCL-90-R), and vitality (SF-36) during 24 to 64 weeks of therapy in this expanded access program with cost recovery (AMP 511). An activity monitor was also utilized in a subset of patients to help evaluate changes in physical activity during the study. Ampligen® dosing (200 to 400 mg twice weekly) and data collection intervals (every 8 weeks) were maintained during the study. Data from 41 severely debilitated FS patients who have received at least 16 weeks of Ampligen® treatment, an investigational drug agent, were available and included in the analyses.

The preliminary findings suggested the KPS increased from a median of 50 at Baseline before treatment to 60 by week 24. The median change in KPS from Baseline was +10 points at weeks 16 and 24. Thirteen patients were entered into an extension phase of the study and received at least 64 weeks of investigational drug Ampligen® treatment. For these thirteen severely debilitated CFS patients, KPS increased from a median of 50 at Baseline to 70 by week 64. The median change in KPS from Baseline was +20 KPS points (weeks 32 - 56) and +30 KPS points (week 64). Significant changes in cognitive deficit, vitality and activity monitor scores were also reported by week 24. The investigational drug treatment long-term was generally well tolerated and the majority of patients (>80%) entered the extension phase of the study receiving treatment beyond 24 weeks.


Please Discuss This Article:   Post a Comment 



[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Vitamins and Supplements

Featured Products

Vitamin D3 Extreme™ by ProHealth Vitamin D3 Extreme™ by ProHealth
50,000 IU Vitamin D3 - Prescription Strength
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
FibroSleep™ by ProHealth FibroSleep™ by ProHealth
The All-in-One Natural Sleep Aid
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium

Natural Remedies

Are You Obtaining the Proper Enzymes? Are You Obtaining the Proper Enzymes?
VIDEO: Healthy Eating and Fibromyalgia VIDEO: Healthy Eating and Fibromyalgia
Protecting Our Eyes Against Time-Induced Damage Protecting Our Eyes Against Time-Induced Damage
Reversing Neurodegeneration with a New Magnesium Compound Reversing Neurodegeneration with a New Magnesium Compound
Preserving Cognitive Function with Aging Preserving Cognitive Function with Aging

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia 101
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS 101
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE
CONTACT US
PRIVACY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing